Drug General Information |
Drug ID |
D0GP3R
|
Former ID |
DNC010747
|
Drug Name |
5-nitroindirubin-3'-oxime
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H10N4O4
|
Canonical SMILES |
C1=CC=C2C(=C1)C(=C(N2)C3=C4C=C(C=CC4=NC3=O)[N+](=O)[O-]<br />)NO
|
InChI |
1S/C16H10N4O4/c21-16-13(10-7-8(20(23)24)5-6-12(10)18-16)15-14(19-22)9-3-1-2-4-11(9)17-15/h1-7,17,19,22H
|
InChIKey |
CJJHTXLGQFLXQK-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Cell division protein kinase 2 |
Target Info |
Inhibitor |
[1]
|
G1/S-specific cyclin E1 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
FoxO signaling pathway
|
Cell cycle
|
Oocyte meiosis
|
p53 signaling pathway
|
PI3K-Akt signaling pathway
|
Progesterone-mediated oocyte maturation
|
Hepatitis B
|
Measles
|
Herpes simplex infection
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Viral carcinogenesis
|
Prostate cancer
|
Small cell lung cancerhsa04110:Cell cycle
|
MicroRNAs in cancer
|
Small cell lung cancer
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
p53 pathway
|
p53 pathway feedback loops 2P00013:Cell cycle
|
Parkinson disease
|
p53 pathway feedback loops 2
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Signaling events mediated by PRL
|
p73 transcription factor network
|
E2F transcription factor network
|
ATR signaling pathway
|
mTOR signaling pathway
|
IL2-mediated signaling events
|
FoxO family signaling
|
FOXM1 transcription factor network
|
BARD1 signaling events
|
p53 pathway
|
Regulation of retinoblastoma proteinprlsignalingeventspathway:Signaling events mediated by PRL
|
PLK3 signaling events
|
Regulation of retinoblastoma protein
|
Reactome
|
G0 and Early G1
|
Activation of ATR in response to replication stress
|
Regulation of APC/C activators between G1/S and early anaphase
|
SCF(Skp2)-mediated degradation of p27/p21
|
Senescence-Associated Secretory Phenotype (SASP)
|
DNA Damage/Telomere Stress Induced Senescence
|
Processing of DNA double-strand break ends
|
G2 Phase
|
Orc1 removal from chromatin
|
Cyclin E associated events during G1/S transition
|
Cyclin A/B1 associated events during G2/M transition
|
p53-Dependent G1 DNA Damage Response
|
Cyclin A:Cdk2-associated events at S phase entry
|
Meiotic recombination
|
Factors involved in megakaryocyte development and platelet productionR-HSA-113510:E2F mediated regulation of DNA replication
|
G1/S-Specific Transcription
|
WikiPathways
|
DNA Damage Response
|
ID signaling pathway
|
DNA Replication
|
G1 to S cell cycle control
|
M/G1 Transition
|
S Phase
|
Meiotic Recombination
|
Aryl Hydrocarbon Receptor
|
ATM Signaling Pathway
|
Retinoblastoma (RB) in Cancer
|
Spinal Cord Injury
|
Integrated Pancreatic Cancer Pathway
|
Oncostatin M Signaling Pathway
|
Prostate Cancer
|
Signaling Pathways in Glioblastoma
|
TSH signaling pathway
|
Integrated Breast Cancer Pathway
|
Integrated Cancer pathway
|
Synthesis of DNA
|
Regulation of DNA replication
|
Mitotic G2-G2/M phases
|
Mitotic G1-G1/S phases
|
Factors involved in megakaryocyte development and platelet production
|
Cell Cycle
|
APC/C-mediated degradation of cell cycle proteins
|
Cell Cycle Checkpoints
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
Parkinsons Disease Pathway
|
Parkin-Ubiquitin Proteasomal System pathway
|
miRNAs involved in DNA damage response
|
miRNA Regulation of DNA Damage Response
|
Androgen receptor signaling pathway
|
References |
REF 1 | J Med Chem. 2010 May 13;53(9):3696-706.5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. |